Alan Barker, MD

Rare disorders studied 

 

  

Biographical information

Dr. Barker received his medical degree from the University of Missouri in Columbia.  He completed an internal medicine residency at the University of Washington and a pulmonary medicine fellowship at the University of California, San Diego.  Dr. Barker currently serves as the medical director of both Respiratory Care, Pulmonary Function and Bronchoscopy at OHSU.  He has been involved in rare disorders for over 22 years and directs one of 13 sites participating in an international Rare Lung Diseases Consortium.

Research interests

Dr. Barker has been recognized as a regional and national expert on alpha-1 antitrypsin (AAT) deficiency and in the treatment of patients with AAT deficiency with augmentation therapy and has published numerous journal articles on the subject. He has been a Principal Investigator of a multi-center study of genetic modifiers in AAT deficiency. He is Principal Investigator of  a multi-center study of sirolimus treatment in lymphanioleiomyomatosis and use of chest to quantify COPD in AAT deficiency and emphysema.  He also studies bronchiectasis.  Dr. Barker directs the OHSU site of the Rare Lung Diseases Consortium.  This consortium is comprised of cooperating clinical centers and patient support organizations that are working with the NIH in a collaborative network to accelerate clinical research and improve the delivery of medical care to individuals with rare lung diseases.  

Rare disorders activities

Served on Medical Advisory Board of the Alpha-1 Antitrypsin Foundation
Served on Executive Committe of the Bronchiectasis Consortium of the COPD Foundation

Online reviews and articles of interest

• Eden E, Hammel J, Rouhani FN et al.  Asthma features in severe alpha-1 antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.  Chest 2003;123(3):765-71
• Barker AF.  Bronchiectasis. N Engl J Med 2002 May 2;346(18):1383-93
• Barker AF, Couch L, Fiel SB et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 Pt 1):481-5
• Schluchter MD, Stoller JK, Barker AF et al. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 2000;161(3 Pt 1):796-801